Next Phase Newsletter

A sector-exclusive life sciences venture and growth equity fund focused on Asia has offices in USA, Hong Kong, and China. The firm is investing from its fifth fund closed in 2019. The firm is stage agnostic, investing as early as seed, growth, and up to pre-IPO opportunities. The firm has a team of investment professionals all with healthcare background. Investment size is USD $5-25 million per company. The firm prefers to lead or co-lead a financing round. The firm focuses on China but also considers opportunities from USA.

In life sciences, the firm is focused on therapeutics with an emphasis on oncology, metabolic disorders, cell therapy, and biologics, etc. The firm is also interested in medical devices and diagnostics. The firm is opportunistic to the indication and the phase of development and will consider products in pre-clinical up to NDA.

The firm is seeking experienced management teams that are going rapidly and emerging as market leaders.  The firm is seeking companies developing technologies that are truly based on high quality science, but also aligned with the potential of attractive financial return. Because the firm focuses its activities in China, the firm will prefer companies outside of China to have a strong China angle. The firm typically requires a board seat or observation rights post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office with over 30 years of investment experience invests in many different sectors including early-stage biotech companies. The firm is based on a network of high-net worth individuals who invest in companies that identify to be of interest. Size of investment can largely vary based on the stage of the company; the firm has invested up to $30M, but initial investments typically range between $5-10M. The firm only considers USA-based opportunities.

The firm is interested in therapeutics and medical device companies, but will not invest in diagnostics or healthcare IT. The firm has several medical device and drug development companies in their portfolio and has no specific preference in terms of stage of development or indication.

The firm seek to work with experienced management teams with strong expertise in their field. The firm usually does not take a board seat or lead financing rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture and expansion capital arm of a large company is currently seeking new opportunities in the life science space. The firm’s initial equity investments range from $5-15M, and increase up to $20M total through subsequent rounds.

The firm is currently most interested in the following Healthcare subsectors: Analytics & Interoperability, Diagnostic Tools, Digital Health, Medical Devices, Pharma Services/IT, and Research Tools.

The firm generally invests in Series B rounds, with some flexibility to go earlier or later in stage. The firm typically looks for companies with up to $10 million of trailing revenue, 50%+ annual growth rate, and visionary management teams with entrepreneurial mindsets. The firm is particularly interested in companies located in underserved geographies with an emphasis on the mid-country.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A strategic healthcare venture investment subsidiary makes equity investments into early- to late-stage companies of approximately $3 million to $10 million initially, with additional capital reserved for follow on financings. It generally invests $4 million to $15 million in a company over the life cycle. The firm only invests in companies that are based in the US.

The firm is currently looking for new opportunities in the Medical Device, Diagnostic, Healthcare IT and Healthcare Services spaces. The firm considers all classes of medical devices and focuses on device companies in the pre-commercial stage. In terms of diagnostics, the firm has a preference for platform technologies and companies whose products are already commercialized. The firm’s Healthcare IT and Healthcare Services investments are typically in the commercial or growth stages.

The firm invests in privately held healthcare companies. The firm looks to invest in companies with a strong management team who can demonstrate relevant experience, depth and capability to build and scale the business and attract customers. The firm typically requests a Board seat or Board observation rights for each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 1996 with offices in Silicon Valley, Beijing, Shanghai, and Tokyo has over $4.2B assets under management and has invested in over 400 companies. In 2019, the firm closed Fund IX at $780M, its largest fund to date. The firm invests mainly in early-stage technology companies (i.e. internet, SaaS, consumer-tech, etc.) with high disruptive potential and seeks to be the first institutional investor, but dedicates a small amount of capital (about 20% of the fund) to later-stage companies as well. Typically, first checks fall in the $2-5M range in Seed to Series A rounds, but the firm has made investments as small as $250K. Overall, the firm invests in over 20 companies per year across North America and Asia. In terms of healthtech specifically, the firm aims to make at least 1-2.

The firm is mainly interested in digital health opportunities and will not consider therapeutics or medical devices. The firm will stray away from anything that involves FDA regulatory approval. Previous investments of the firm include a Google Glass-powered remote scribe platform that improves the workflow of physicians, an AI engine that matches cancer patients with clinical trials, a wearable health tracker for healthy lifestyle management, etc. Companies do not need to be generating revenue prior to investment.

The firm invests in private companies with strong technology and can work with different kinds of management teams that are ideally devoted full-time to the company. The firm will almost always act as the lead investor and seek board representation, staying actively involved in their portfolio companies. The firm prefers to have a syndicate of co-investors invest alongside the firm, but this is not an absolute requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

A firm operates 80+ hospitals across Asia, the Middle East and Turkey has an innovation office that acts as a corporate VC arm, which has committed capital of $80 million to invest in the digital health space. The firm typically invests $5-10 million per opportunity, and will invest in companies worldwide that are interested in expanding into Asia.

The firm only invests in the digital health space. The firm is interested in many areas of digital health, diagnostics, and tech-enabled healthcare services, including wellness, digital therapeutics, AI, healthcare data, remote monitoring, chronic disease management, etc. The firm does not invest in biopharma or medtech.

The firm will invest globally, and is focused on startups that are interested in expanding into Asia.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

A venture capital firm founded in 2019 and headquartered in Whitefish, Montana is seeking opportunities across all sectors of life sciences with a focus on biotechnologies, digital health, and infosec. The firm will engage in seed to series B rounds, but mostly looking to invest in series A. A typical allocation can range from 4 – 8 million USD. The firm will invest in companies that are based/headquartered in the US. The firm prefers to lead the investment round and will seek board seats when leading.

The firm is interested in novel technologies that address significant unmet needs in life sciences. The firm is most focused on biotechnologies and digital health but is open to considering all sectors in life sciences. Within the therapeutics sector, the firm is most interested in companies with a diversified pipeline in pre-clinical and clinical trial stages. The firm will consider opportunities in any indication, but has particular interest in oncology, immunology, and neurology. Within the digital health sector, the firm is interested in companies focused on value-based care models and technologies that incorporate machine learning and AI. The firm is also opened to considering medical devices and diagnostics companies of all stages of development. The firm is opportunistic in terms of subsectors and indications in these sectors.

The firm has no strict company or management team requirements, but prefers to work with companies led by founders with strong scientific and technical expertise. The firm does look to take an active role in helping the company to grow.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.